Udoamaka Ezuruike

Udoamaka Ezuruike

Auto-generated profile, based on publicly available information

Udoamaka Ezuruike

Certara Predictive Technologies, Level 2-Acero, 1 Concourse Way, Sheffield, S1 2BJ, Sheffield, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2022 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
UEUdoamaka Ezuruike
Udoamaka Ezuruike
MZMian Zhang
Mian Zhang
APAmita Pansari
Amita Pansari
MMMailys De Sousa Mendes
Mailys De Sousa Mendes
XPXian Pan
Xian Pan
IGIain Gardner
Iain Gardner
The Simcyp Simulator is a software platform for population physiologically‐based pharmacokinetic (PBPK) modeling and simulation. It links in vitro data to in vivo absorption, distribution, metabolism, excretion and pharmacokinetic/pharmacodynamic outcomes to explore clinical scenarios and support drug development decisions, including regulatory submissions and drug labels. This tutorial describes the different input parameters required, as well as the considerations needed when developing a PBPK model within the Simulator, for a small molecule intended for oral administration. A case study showing the development and application of a PBPK model for ondansetron is herein used to aid the understanding of different PBPK model development concepts.

10 April 2018 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
UEUdoamaka Ezuruike
Udoamaka Ezuruike
HHHelen Humphries
Helen Humphries
MDMaurice Dickins
Maurice Dickins
SNSibylle Neuhoff
Sibylle Neuhoff
IGIain Gardner
Iain Gardner
KYKaren Rowland Yeo
Karen Rowland Yeo
Current formulations of combined oral contraceptives (COC) containing ethinylestradiol (EE) have ≤35 μg due to increased risks of cardiovascular diseases (CVD) with higher doses of EE. Low‐dose formulations however, have resulted in increased incidences of breakthrough bleeding and contraceptive failure, particularly when coadministered with inducers of cytochrome P450 enzymes (CYP). The developed physiologically based pharmacokinetic model quantitatively predicted the effect of CYP3A4 inhibition and induction on the pharmacokinetics of EE. The predicted Cmax and AUC ratios when coadministered with voriconazole, fluconazole, rifampicin, and carbamazepine were within 1.25 of the observed data. Based on published clinical data, an AUCss value of 1,000 pg/ml.h was selected as the threshold for breakthrough bleeding. Prospective application of the model in simulations of different doses of EE (20 μg, 35 μg, and 50 μg) identified percentages of the population at risk of breakthrough bleeding alone and with varying degrees of CYP modulation.

16 January 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
UEUdoamaka Ezuruike
Udoamaka Ezuruike
LCLiam Curry
Liam Curry
OHOliver Hatley
Oliver Hatley
IGIain Gardner
Iain Gardner

17 July 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
UEUdoamaka Ezuruike
Udoamaka Ezuruike
JDJean Dinh
Jean Dinh
EEEman El-Khateeb
Eman El-Khateeb
ABAlex Blenkinsop
Alex Blenkinsop
OHOliver James Hatley
Oliver James Hatley
IGIain Gardner
Iain Gardner
Ethnic variabilities can affect the outcome of drug pharmacokinetics (PK) and drug–drug interactions (DDI). This work aimed to develop four North American (NA) sub‐populations: White, African American, Asian American, and Hispanic_Latino suitable for physiologically based pharmacokinetic (PBPK) modeling and simulations. Demographic data and tissue weight/volume, blood flows, cardiac output, plasma protein levels, hematocrit, enzyme and transporter abundances/frequencies, serum creatinine, glomerular filtration rate, and gastrointestinal transit times for the different populations were collated. Equations describing various covariate relationships for these physiological parameters were developed for each ethnicity. Some key population differences that can affect drug PK were higher CYP3A5 and OATP1B1 population mean abundances for African Americans and lower CYP3A4 and OATP1B1 population mean abundances for Asian Americans. The most common CYP2C9 alleles in the White as well as the Asian populations are the *1, *2, and *3 alleles. However, additional lower‐activity alleles (*5, *6, *8, and *11) were also shown to occur among the African Americans and Hispanic_Latino subjects. Clinical studies reporting population specific PK profiles (6 studies) or results from a mixed NA population (14 studies including 6 DDI studies) were simulated, and the simulated data were within two‐fold of the observed data. PBPK simulations using the 4 NA population files and repaglinide as a probe compound predicted significant differences in the drug exposure for the Asians, African Americans, and White subjects. In conclusion, the developed population files can aid drug development for specific subgroups of the diverse NA population by accounting for variabilities in drug kinetics and DDI consequences.

4 November 2025 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
HMHarry P. Moore
Harry P. Moore
KCKuan-Fu Chen
Kuan-Fu Chen
AHAki T. Heikkinen
Aki T. Heikkinen
SNSibylle Neuhoff
Sibylle Neuhoff
UEUdoamaka Ezuruike
Udoamaka Ezuruike
FSFelix Stader
Felix Stader